Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Testosterone replacement therapy post-radical prostatectomy reduces biochemical recurrence
Key clinical point: Testosterone replacement therapy after radical prostatectomy significantly reduces biochemical recurrence (BCR) and delays time to BCR.
Major finding: In all, 7.2% of patients experienced BCR in the testosterone therapy vs. 12.6% in the control groups. The testosterone therapy was associated with a reduction in the risk of BCR at an average follow-up of 3.4 years (hazard ratio, 0.54). In men destined to recur, time to BCR was delayed by 1.5 years in the testosterone therapy group.
Study details: Retrospective, frequency matched, case-control study compared rates and time to prostate cancer BCR after radical prostatectomy in men receiving (n = 152) vs. not receiving the testosterone therapy (n = 419).
Disclosures: No study sponsor was identified. The authors declared no conflict of interest.
Ahlering TE et al. BJU Int. 2020 Mar 2. doi: 10.1111/bju.15042.